Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes by Martis S, Peter I, Hulot J-S, Kornreich R, Desnick R J, Scott S A in The pharmacogenomics journal (2012).

[PMID: 22491019] PubMed


To determine CYP2C19 and CYP2C8 allele frequencies, 28 coding and/or functional variants were genotyped in 1250 African-American, Asian, Caucasian, Hispanic and Ashkenazi Jewish (AJ) individuals. The combined CYP2C19 variant allele frequencies ranged from ¿0.30 to 0.41; however, the CYP2C8 frequencies were much lower (¿0.04-0.13). After incorporating previously reported CYP2C9 genotyping results from these populations (36 total CYP2C variants), 16 multi-ethnic CYP2C haplotypes were inferred with frequencies >0.5%. Notably, the 2C19*17-2C9*1-2C8*2 haplotype was identified among African-Americans (8%) and Hispanics (2%), indicating that CYP2C19*17 does not always tag a CYP2C haplotype that encodes efficient CYP2C-substrate metabolism. The 2C19*1-2C9*2-2C8*3 haplotype was identified in all populations except African-Americans and additional novel haplotypes were identified in selected populations (for example, 2C19*2-2C9*1-2C8*4 and 2C19*4B-2C9*1-2C8*1), together indicating that both CYP2C19*17 and *2 can be linked with other CYP2C loss-of-function alleles. These results have important implications for pharmacogenomic association studies involving the CYP2C locus and are clinically relevant when administering CYP2C-substrate medications.The Pharmacogenomics Journal advance online publication, 10 April 2012; doi:10.1038/tpj.2012.10.

[ hide abstract ]

Discussed In Paper


Rx Annotations

No dosing information annotated.